| Date Filed | Type | Description |
| 06/12/2023 |
SC 13G/A
| ALGER ASSOCIATES INC reports a 0% stake in Core Laboratories N.V. |
| 05/02/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 04/27/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/03/2023 |
4
| van Dijken Eeuwijk Monique (Director) has filed a Form 4 on CORE LABORATORIES N V|
Txns:
| Exercised 5,485 options to buy
@ $0 |
|
| 04/03/2023 |
4
| Temeng Kwaku (Director) has filed a Form 4 on CORE LABORATORIES N V|
Txns:
| Granted 6,419 options to buy
@ $0
Exercised 5,485 options to buy
@ $0 |
|
| 04/03/2023 |
4
| Straughen Michael (Director) has filed a Form 4 on CORE LABORATORIES N V|
Txns:
| Paid exercise price by delivering 2,524 shares
@ $22.05, valued at
$55.7k
Granted 6,419 options to buy
@ $0
Exercised 5,485 options to buy
@ $0 |
|
| 04/03/2023 |
4
| Murray Katherine (Director) has filed a Form 4 on CORE LABORATORIES N V|
Txns:
| Granted 6,419 options to buy
@ $0
Exercised 5,485 options to buy
@ $0 |
|
| 04/03/2023 |
4
| Klingensmith Harvey Robert (Director) has filed a Form 4 on CORE LABORATORIES N V|
Txns:
| Granted 6,419 options to buy
@ $0
Exercised 5,485 options to buy
@ $0 |
|
| 04/03/2023 |
4
| Carnes Martha Z. (Director) has filed a Form 4 on CORE LABORATORIES N V|
Txns:
| Granted 6,419 options to buy
@ $0
Exercised 5,485 options to buy
@ $0 |
|
| 02/28/2023 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 02/14/2023 |
SC 13G/A
| ALGER ASSOCIATES INC reports a 8.3% stake in Core Laboratories N.V. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| EARNEST PARTNERS LLC reports a 7.7% stake in CORE LABORATORIES N.V. |
| 02/03/2023 |
8-K
| Quarterly results |
| 02/01/2023 |
8-K
| Quarterly results |
| 01/26/2023 |
SC 13G/A
| BlackRock Inc. reports a 12.6% stake in CORE LABORATORIES N V |
| 01/20/2023 |
SC 13G/A
| BlackRock Inc. reports a 12.6% stake in CORE LABORATORIES N V |
| 01/17/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/17/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/17/2023 |
8-K
| Quarterly results |
| 01/04/2023 |
4
| Gresham Gwendolyn (SVP) has filed a Form 4 on CORE LABORATORIES N V|
Txns:
| Paid exercise price by delivering 4,722 shares
@ $20.27, valued at
$95.7k
Exercised 12,000 options to buy
@ $0 |
|
| 01/04/2023 |
4
| Hill Christopher Scott (SVP & CFO) has filed a Form 4 on CORE LABORATORIES N V|
Txns:
| Paid exercise price by delivering 12,470 shares
@ $20.27, valued at
$252.8k
Exercised 31,688 options to buy
@ $0 |
|
| 01/04/2023 |
4
| Daniels Kevin (CAO & Treasurer) has filed a Form 4 on CORE LABORATORIES N V|
Txns:
| Paid exercise price by delivering 2,361 shares
@ $20.27, valued at
$47.9k
Exercised 6,000 options to buy
@ $0 |
|
| 01/04/2023 |
4
| Bruno Lawrence (Chairman and CEO) has filed a Form 4 on CORE LABORATORIES N V|
Txns:
| Paid exercise price by delivering 35,892 shares
@ $20.27, valued at
$727.5k
Exercised 91,212 options to buy
@ $0 |
|
| 12/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/04/2022 |
8-K
| Quarterly results |
| 10/27/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/26/2022 |
8-K
| Quarterly results |
| 10/03/2022 |
4
| Tattoli Mark Damian (SVP, Gen Counsel & Secretary) has filed a Form 4 on CORE LABORATORIES N V|
Txns:
| Paid exercise price by delivering 276 shares
@ $13.48, valued at
$3.7k
Exercised 700 options to buy
@ $0 |
|
| 08/02/2022 |
4
| Tattoli Mark Damian (SVP, Gen Counsel & Secretary) has filed a Form 4 on CORE LABORATORIES N V|
Txns:
| Paid exercise price by delivering 112 shares
@ $18.02, valued at
$2k
Paid exercise price by delivering 54 shares
@ $18.02, valued at
$973.1
Exercised 250 options to buy
@ $0
Exercised 120 options to buy
@ $0 |
|
| 07/28/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/27/2022 |
8-K
| Quarterly results|
Docs:
|
"CORE LABORATORIES N.V. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended % Variance June 30, 2022 June 30, 2021 vs. Q1-22 vs. Q2-21 REVENUE $120,898 $115,300 $118,745 4.9% 1.8% OPERATING EXPENSES: Costs of services and sales 97,957 96,952 93,841 1.0% 4.4% General and administrative expense 6,847 12,545 9,670 % % Depreciation and amortization 4,360 4,557 4,751 % % Other expense, net 82 1,637 % NM Total operating expenses 109,246 115,691 105,945 % 3.1% OPERATING INCOME 11,652 12,800 NM % Interest expense 2,707 2,644 2,530 2.4% 7.0% Income from continuing operations before income tax expense 8,945 10,270 NM % Income tax expense 1,789 2,053 NM % Income from continuing operations 7,156 8,217 NM % Net income 7,156 8,217 NM % Net income attributable to non-control..." |
|
|